<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">WJCD</journal-id><journal-title-group><journal-title>World Journal of Cardiovascular Diseases</journal-title></journal-title-group><issn pub-type="epub">2164-5329</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/wjcd.2018.83021</article-id><article-id pub-id-type="publisher-id">WJCD-83414</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Blood Pressure Patterns and Factors Associated with Relative Hypertension among Steady State Sickle Cell Disease Patients in Kinshasa, Democratic Republic of the Congo: A Cross-Sectional Study
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>P.</surname><given-names>I. Mboliasa</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>F.</surname><given-names>B. Lepira</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>J.</surname><given-names>R. Makulo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>A.</surname><given-names>Nkodila</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>E.</surname><given-names>K. Sumaili</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>J.</surname><given-names>B. Bukabau</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>V.</surname><given-names>M. Mokoli</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>A.</surname><given-names>L. Longo</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>C.</surname><given-names>V. Zinga</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>F.</surname><given-names>M. P. Kanjingulu</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Y.</surname><given-names>M. Nlandu</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Y.</surname><given-names>M. Engole</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>M.</surname><given-names>M. Mukendi</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>E.</surname><given-names>M. Kadima</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>C.</surname><given-names>K. Ilunga</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>P.</surname><given-names>M. Ekulu</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>N.</surname><given-names>M. N. Nseka</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>Field Epidemiology and Laboratory Training Program, Kinshasa School of Public Health, Kinshasa, Congo</addr-line></aff><aff id="aff1"><addr-line>Division of Nephrology, Department of Internal Medicine, University of Kinshasa Hospital, Kinshasa, Congo</addr-line></aff><aff id="aff3"><addr-line>Division of Nephrology, Department of Pediatric, University of Kinshasa Hospital, Kinshasa, Congo</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>lepslepira@yahoo.fr(FBL)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>26</day><month>03</month><year>2018</year></pub-date><volume>08</volume><issue>03</issue><fpage>217</fpage><lpage>228</lpage><history><date date-type="received"><day>6,</day>	<month>February</month>	<year>2018</year></date><date date-type="rev-recd"><day>26,</day>	<month>March</month>	<year>2018</year>	</date><date date-type="accepted"><day>29,</day>	<month>March</month>	<year>2018</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Background:
   Although systemic hypertension is rarely seen in steady state sickle cell disease (SCD), relative hypertension has been reported to be associated with an increased risk of cardiovascular and renal complications. <b>Objective:</b> To determine the prevalence of BP patterns and assess factors associated with relative hypertension in
  
  sickle cell anemia (SCA) adult patients. <b>Methods:</b> Clinical data and office BP were obtained from 103 consecutive steady-state SCA adult patients (mean age 26 &#177; 7.9 years, 66% females, 22.3% on hydroxyurea) attending four healthcare centers providing SCD-specific care in Kinshasa. Seated BP was measured using an automated electronic device. Three consecutive blood pressure measurements were taken with 2 minutes interval between readings and the average of the 2
   
  last readings was considered for the analyses. Normal BP, relative hypertension and systemic hypertension were defined as BP 
  &lt; 
  120/70 mmHg, 120
   
  -
   
  139/70
   
  -
   
  89 mmHg and ≥140/90 mmHg, respectively. 
  <b>Results:</b>
   Normal BP, relative hypertension and systemic hypertension were observed in 56
   
  (54%), 43
  
  (42%) and 4 (4%) of SCA patients, respectively. In multivariate analysis, factors associated with relative hypertension were leg ulcer (aOR 2.05; 95%CI 1.77
   
  -
   
  5.18; p
   
  =
   
  0.016), central obesity (aOR 3.32; 95%CI 1.28
   
  -
   
  6.24; p
   
  =
   
  0.001), smoking (aOR 5.02; 95%CI 1.51
   
  -
   
  9.50; p
   
  =
   
  0.017), and microalbumiuria
   
  (aOR 3.44; 95%CI 1.44
   
  -
   
  5.76; p =
   
  0.035). <b>Conclusion:</b>
  <b> </b>
  Relative hypertension was a common finding in the present case series and associated with traditional cardiovascular risk factor as well as factors specific to SCD highlighting the need for measures to prevent its progression towards systemic hypertension and associated cardiovascular and renal disease.
 
</p></abstract><kwd-group><kwd>Relative Hypertension</kwd><kwd> Prevalence</kwd><kwd> Associated Factors</kwd><kwd> Sickle Cell Anemia</kwd><kwd> Black Africans</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>In contrast to the general population, a seeming finding in sickle cell disease (SCD) is that patients do not usually suffer from a high prevalence of systemic hypertension in spite of extended endothelial dysfunction, chronic inflammation and vasculopathy [<xref ref-type="bibr" rid="scirp.83414-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.83414-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.83414-ref3">3</xref>] . However, recent data indicate that blood pressure (BP) abnormalities such as relative systemic hypertension (BP ≥ 120 - 139/70 - 89 mmHg) and increased pulse pressure (PP ≥ 60 mmHg) or systolic hypertension are associated with an increased pulmonary, renal and cardiovascular disease (CVD) risk [<xref ref-type="bibr" rid="scirp.83414-ref1">1</xref>] [<xref ref-type="bibr" rid="scirp.83414-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.83414-ref4">4</xref>] [<xref ref-type="bibr" rid="scirp.83414-ref5">5</xref>] [<xref ref-type="bibr" rid="scirp.83414-ref6">6</xref>] . In addition, the lack of nocturnal BP dip using ambulatory BP monitoring (ABPM), a well-known risk factor for the development and progression of renal and cardiovascular disease, has been reported to play an important role in SCD-associated target organ involvement [<xref ref-type="bibr" rid="scirp.83414-ref5">5</xref>] . Therefore, the assessment of office or clinic BP patterns and/or 24-hour circadian BP patterns on ABPM, especially in SCD patients with kidney involvement (e.g. microalbuminuria) could help reducing the risk of renal disease progression and CVD development.</p><p>In Democratic Republic of the Congo (DRC), the prevalence of SCD is estimated to be of 2% [<xref ref-type="bibr" rid="scirp.83414-ref7">7</xref>] and renal involvement in terms of microalbuminuria is a common finding [<xref ref-type="bibr" rid="scirp.83414-ref8">8</xref>] [<xref ref-type="bibr" rid="scirp.83414-ref9">9</xref>] . However, patterns of office BP as well as the prevalence and factors associated with relative hypertension in SCD patients have not yet been evaluated. We took advantage of the availability of data from a cross-sectional study of renal function in steady-state SCA adult patients to perform a post-hoc analysis on the prevalence and factors associated with relative hypertension.</p></sec><sec id="s2"><title>2. Patients and Methods</title><p>From December 15, 2016 to March 31, 2017, a multicenter cross-sectional study was conducted on consecutive steady-state adult patients with electrophoresis diagnosis of SCD attending four healthcare centers (Centre Hospitalier Monkole/CHM, Centre d’An&#233;mie SS Mabanga/CASM, H&#244;pital des Soeurs de Kingasani/HSKand Centre Saint Crispin/CSK) providing specific SCD care in Kinshasa, the capital City. Patients were asked to participate to the study on a volunteer basis. The study protocol was reviewed and approved by the Ethics Committee of Kinshasa School of Public Health, University of Kinshasa (ESP/CE/090/2016). Clinical Steady-state was defined as the absence within the last two months prior to the study of vaso-occlusive crisis (VOC) or hemolysis, blood transfusion, acute chest syndrome, fever or any acute illness [<xref ref-type="bibr" rid="scirp.83414-ref10">10</xref>] . Patients with illnesses known to interfere with urinary albumin excretion such as diabetes, HIV infection, hepatitis B or C were excluded. Variables collected for each patient, based on interviews and physical examination at the time of visit and on data drawn from clinical records, were demographic (sex, age), past medical history (number of blood transfusion, pulmonary artery hypertension, vascular occlusive crisis/VOC, leg ulcer, priapism, aseptic osteonecrosis/AON, family and personal hypertension, family diabetes, stroke, hydroxyurea use, alcohol intake, smoking) and physical examination (height, weight, BP, and waist circumference). A standardized questionnaire administered by trained interviewers was used to collect medical information. Patients who smoked at least one cigarette per day at the time of consultation were classified as active smokers [<xref ref-type="bibr" rid="scirp.83414-ref11">11</xref>] . Excessive alcohol intake was defined by regular intake of ≥2 glasses per day of beer or equivalent for at least 1 year knowing that 1 glass of beer contain 10 g of alcohol [<xref ref-type="bibr" rid="scirp.83414-ref12">12</xref>] . Height and weight were measured patients without heavy garments and shoes using a wooden vertical stadiometer and SECA scale (Vogel etHalk, Hamburg, Deutschland), respectively. Body mass index (Kg/m<sup>2</sup>) was calculated as weight (Kg) divided by (height, m<sup>2</sup>); underweight, overweight and obesity were defined as BMI &lt; 18.5, 18.5 - 29.9 and ≥30 Kg/m<sup>2</sup>, respectively [<xref ref-type="bibr" rid="scirp.83414-ref13">13</xref>] . Waist circumference (WC) was measured to the nearest 0.1 cm at the mid-point between the lower costal margin and the level of the anterior superior iliac crest using a taperecord. Central obesity was defined as WC &gt; 80 cm and &gt;94 cm in women and men, respectively [<xref ref-type="bibr" rid="scirp.83414-ref14">14</xref>] . Seated BP measurement was taken on the left arm by a trained nurse after 5 minutes of rest, using an automated electronic sphygmomanometer OMRON HEM 907 (Omron Matsusaka Co. Ltd., Kyoto Japan). Three consecutive BP measurements were taken with 2 minutes interval between readings and the average of the 2 last readings was considered for analyses. Pulse pressure (PP, mmHg) and mean arterial BP (MAP, mmHg) were calculated as systolic blood pressure (SBP) minus diastolic BP (DBP) and DBP + PP/3, respectively. PP &gt; 60 mmHg defined increased PP levels, a marker of arterial stiffness [<xref ref-type="bibr" rid="scirp.83414-ref15">15</xref>] . Normal BP, relative hypertension and systemic hypertension were defined BP &lt; 120/70 mmHg, 120 - 139/70 - 89 mmHg and ≥140/90 mmHg, respectively [<xref ref-type="bibr" rid="scirp.83414-ref2">2</xref>] .</p><p>A 12-hour overnight venous blood sample was obtained for each patient and processed at the Reference Laboratory of the DRC National AIDS Control Program using an automatic device for full blood count (SYSMEX XP-300, Ville, Pays), uric acid blood urea nitrogen and serum creatinine (COBAS C111). Serum uric levels &gt; 360 &#181;mol/l and 420 &#181;mol/l defined hyperuricemia in women and men, respectively [<xref ref-type="bibr" rid="scirp.83414-ref16">16</xref>] . Renal function was evaluated by the estimation of glomerular filtration rate (GFR) using the Chronic Kidney Disease Epidemiology (CKD-EPI) without adjustment for ethnicity [<xref ref-type="bibr" rid="scirp.83414-ref17">17</xref>] . eGFR &lt; 60 ml/min/1.73 m<sup>2</sup> defined reduced kidney function [<xref ref-type="bibr" rid="scirp.83414-ref17">17</xref>] . eGFR &gt; 130 ml/min/1.73 m<sup>2</sup> and &gt;140 ml/min/1.73 m<sup>2</sup> definedglomerular hyperfiltrationin women and men, respectively [<xref ref-type="bibr" rid="scirp.83414-ref18">18</xref>] . Urinary albumin excretion was determined in spot morning urine (DCA Vantage SYSMEX) and express as albumin creatinine ratio (ACR, mg/g). ACR 30 - 299 mg/g and ≥300 mg/g defined microalbuminuria and macroalbuminuria, respectively [<xref ref-type="bibr" rid="scirp.83414-ref19">19</xref>] .</p><p>Statistical analyses were performed using the Statistical Package for Social Sciences (SSPS Inc, Chicago, Illinois, USA) version 17.0 software. Results are summarized as counts and percentages for qualitative variables and as mean &#177; standard deviation (SD) for quantitative variables. Comparisons of means of two or more than two groups and of proportions used Student t-test, one way analysis of variance (ANOVA) and chi-square test, respectively. Independent factors associated with relative hypertension were assessed using multivariate logistic regression analysis. A p-value &lt; 0.05 defined the level of statistical significance.</p></sec><sec id="s3"><title>3. Results</title><p>The present cross-sectional study included 103 steady state SCD adult patients of whom 66% were females (<xref ref-type="table" rid="table1">Table 1</xref>). Their mean age, BMI, SBP, DBP, MP and PP were 26 &#177; 7.9 years, 18.8 &#177; 2.6 Kg/m<sup>2</sup>, 109.2 &#177; 13.2 mmHg, 67.6 &#177; 10.2 mmHg, 81.5 &#177; 10.1 mmHg and 41.7 &#177; 10.7 mmHg, respectively. The proportions of patients with previous history of leg ulcer, aseptic osteonecrosis (AON), more than 3 blood transfusions, VOCand priapism were 25.2%, 13.6%, 12.6%, 5.8% and 5.8%, respectively. Nearly 2 in 10 patients were receiving hydroxycarbamide (HU). Their mean Hb level, reticulocytes count, uric acid, eGFR (CKD-EPI) and ACR levelswere 76 &#177; 15 g/l, 9.6% &#177; 3.2%, 374.85 &#177; 113.05 &#181;mol/l, and 164.7 &#177; 36.4 ml/min/1.73 m<sup>2</sup> and 38.3 &#177; 6.3 mg/g, respectively.</p><p>BP patterns of the study population are depicted in <xref ref-type="fig" rid="fig1">Figure 1</xref>. Normal BP, relative hypertension and systemic hypertension were observed in 56 (54%), 43</p><p>(42%) and 4 (4%) patients, respectively. Compared to patients with normal BP (<xref ref-type="table" rid="table1">Table 1</xref>), those with relative hypertension had in average significantly higher levels of Ht (24.0 &#177; 4, 0 vs 21, 9 &#177; 4, 9%; p = 0.026). They also had a higher proportion of leg ulcer (31.9% vs 19.6%; p = 0.011) and lower proportion of underweight (38.6% vs 51.8%; p = 0.012), aseptic osteonecrosis (8.5% vs 17.9%; p = 0.013) and subjects receiving hydroxycarbamide (14.9% vs 28.6%; p = 0.007). <xref ref-type="table" rid="table2">Table 2</xref> gives the distribution of cardiovascular risk factors in the study population as a whole and according to BP pattern status. Patients with relative hypertension had a significantly higher proportion of smokers (11% vs 0%; p = 0.018), increased PP (13% vs 0%; p = 0.008), low Hb levels (47% vs 39%; p = 0.028), hyperuricemia (57% vs 29%; p = 0.036), microalbuminuria (45 vs 18; p 0.038) and lower proportion of underweight (38% vs 52%; p = 0.012).</p><p>Univariate and multivariate factors associated with relative hypertension are summarized in Tables 3. In univariate analysis, leg ulcer, central obesity, smoking, hyperuricemia, microalbuminuria and low Hb levels emerged as the main factors associated with relative hypertension. However, in multivariate analysis, the strength of the associations observed in univariate analysis persisted only for leg ulcer (aOR 2.05; 95%CI 1.77 - 5.18; p = 0.016), central obesity (aOR 3.32; 95%CI 1.28 - 6.24; p = 0.001), smoking (aOR 5.02; 95%CI 1.51 - 9.50; p = 0.017), and microalbumiuria (aOR 3.44; 95%CI 1.44 - 5.76; p = 0.035).</p></sec><sec id="s4"><title>4. Discussion</title><p>The main findings of the present cross-sectional study are as follow. First, relative hypertension was a common finding in the preset case series whereas systemic hypertension was rarely seen. Second, leg ulcer, central obesity, smoking and microalbuminuria were the main clinical factors significantly associated with relative hypertension.</p><p>Nearly half of steady-state SCD patients had relative hypertension in the present study. Our prevalence is similar to that of 45% reported by Benneh-Akwasi Kuma et al. in Ghana [<xref ref-type="bibr" rid="scirp.83414-ref20">20</xref>] as well as of 44% found by Makubi et al. [<xref ref-type="bibr" rid="scirp.83414-ref21">21</xref>] and Gordeuk et al. [<xref ref-type="bibr" rid="scirp.83414-ref6">6</xref>] . However, it is somewhat higher than that of 17% found by Becker et al. [<xref ref-type="bibr" rid="scirp.83414-ref5">5</xref>] and Bodas et al. [<xref ref-type="bibr" rid="scirp.83414-ref4">4</xref>] , respectively. The observed disparity in relative hypertension prevalence could be explained by differences in methodology, patient’s clinical characteristics and thresholds used to define relative hypertension. The mechanisms underlying the relative BP increase in SCD patients are not well understood. However, alterations in blood viscosity may substantially contribute to increase BP [<xref ref-type="bibr" rid="scirp.83414-ref15">15</xref>] . Indeed, hemolysis-induced oxidative stress and subsequent endothelial dysfunction as well as unavailability of nitric oxide (NO) can lead to platelet activation, aggregation and subsequent increase in blood viscosity and peripheral vascular resistance according to Poiseuille law [<xref ref-type="bibr" rid="scirp.83414-ref16">16</xref>] . Relative hypertension has been reported to be associated with an increased risk for renal and pulmonary complications. Indeed, Gordeuck et al. [<xref ref-type="bibr" rid="scirp.83414-ref6">6</xref>] reported over a two years follow up trends for more progression to elevated serum</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Clinical and biological characteristics of the study population as a whole and according to BP pattern status</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variables</th><th align="center" valign="middle" >All n = 103</th><th align="center" valign="middle" >Normal BP n = 56</th><th align="center" valign="middle" >Relative HT n = 47</th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle" >Gender, n(%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.423</td></tr><tr><td align="center" valign="middle" >M</td><td align="center" valign="middle" >35(34.0)</td><td align="center" valign="middle" >20(35.7)</td><td align="center" valign="middle" >15(31.9)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >F</td><td align="center" valign="middle" >68(66.0)</td><td align="center" valign="middle" >36(64.3)</td><td align="center" valign="middle" >32(68.1)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Age (years)</td><td align="center" valign="middle" >26.2 &#177; 7.9</td><td align="center" valign="middle" >25.7 &#177; 8.1</td><td align="center" valign="middle" >26.8 &#177; 7.8</td><td align="center" valign="middle" >0.462</td></tr><tr><td align="center" valign="middle" >HT family (n, %)</td><td align="center" valign="middle" >41(39.8)</td><td align="center" valign="middle" >20(35.7)</td><td align="center" valign="middle" >21(44.7)</td><td align="center" valign="middle" >0.234</td></tr><tr><td align="center" valign="middle" >DS family (n, %)</td><td align="center" valign="middle" >25(24.3)</td><td align="center" valign="middle" >14(25)</td><td align="center" valign="middle" >11(23.4)</td><td align="center" valign="middle" >0.518</td></tr><tr><td align="center" valign="middle" >SBP (mmHg)</td><td align="center" valign="middle" >109.2 &#177; 13.2</td><td align="center" valign="middle" >102.2 &#177; 9.0</td><td align="center" valign="middle" >127.6 &#177; 12.6</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >DBP (mmHg)</td><td align="center" valign="middle" >67.6 &#177; 10.2</td><td align="center" valign="middle" >60.6 &#177; 6.2</td><td align="center" valign="middle" >75.9 &#177; 7.4</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >MAP (mmHg)</td><td align="center" valign="middle" >81.5 &#177; 10.1</td><td align="center" valign="middle" >74.5 &#177; 6.3</td><td align="center" valign="middle" >89.8 &#177; 6.9</td><td align="center" valign="middle" >&lt;0.001</td></tr><tr><td align="center" valign="middle" >PP (mmHg)</td><td align="center" valign="middle" >41.7 &#177; 10.7</td><td align="center" valign="middle" >41.6 &#177; 7.6</td><td align="center" valign="middle" >41.7 &#177; 13.7</td><td align="center" valign="middle" >0.935</td></tr><tr><td align="center" valign="middle" >BMI (Kg/m<sup>2</sup>)</td><td align="center" valign="middle" >18.8 &#177; 2.6</td><td align="center" valign="middle" >18.6 &#177; 2.7</td><td align="center" valign="middle" >19.0 &#177; 2.5</td><td align="center" valign="middle" >0.441</td></tr><tr><td align="center" valign="middle" >WC, m</td><td align="center" valign="middle" >0.7 &#177; 0.1</td><td align="center" valign="middle" >0.7 &#177; 0.1</td><td align="center" valign="middle" >0.7 &#177; 0.01</td><td align="center" valign="middle" >0.236</td></tr><tr><td align="center" valign="middle" >Transfusion/yr ≥ 3 (n, %)</td><td align="center" valign="middle" >13(12.6)</td><td align="center" valign="middle" >7(12.5)</td><td align="center" valign="middle" >6(12.8)</td><td align="center" valign="middle" >0.599</td></tr><tr><td align="center" valign="middle" >VOC/yr ≥3 (n, %)</td><td align="center" valign="middle" >6(5.8)</td><td align="center" valign="middle" >3(5.4)</td><td align="center" valign="middle" >3(6.4)</td><td align="center" valign="middle" >0.574</td></tr><tr><td align="center" valign="middle" >HU (n, %)</td><td align="center" valign="middle" >23(22.3)</td><td align="center" valign="middle" >16(28.6)</td><td align="center" valign="middle" >7(14.9)</td><td align="center" valign="middle" >0.007</td></tr><tr><td align="center" valign="middle" >AON (n, %)</td><td align="center" valign="middle" >14(13.6)</td><td align="center" valign="middle" >10(17.9)</td><td align="center" valign="middle" >4(8.5)</td><td align="center" valign="middle" >0.013</td></tr><tr><td align="center" valign="middle" >Leg ulcer (n, %)</td><td align="center" valign="middle" >26(25.2)</td><td align="center" valign="middle" >11(19.6)</td><td align="center" valign="middle" >15(31.9)</td><td align="center" valign="middle" >0.011</td></tr><tr><td align="center" valign="middle" >Priapism (n, %)</td><td align="center" valign="middle" >6(5.8)</td><td align="center" valign="middle" >4(7.1)</td><td align="center" valign="middle" >2(4.3)</td><td align="center" valign="middle" >0.426</td></tr><tr><td align="center" valign="middle" >Hb (g/l)</td><td align="center" valign="middle" >76.0 &#177; 15.0</td><td align="center" valign="middle" >74.0 &#177; 16.0</td><td align="center" valign="middle" >79.0 &#177; 13.0</td><td align="center" valign="middle" >0.053</td></tr><tr><td align="center" valign="middle" >Ht(%)</td><td align="center" valign="middle" >22.9 &#177; 4.6</td><td align="center" valign="middle" >21.9 &#177; 4.9</td><td align="center" valign="middle" >24.0 &#177; 4.0</td><td align="center" valign="middle" >0.026</td></tr><tr><td align="center" valign="middle" >Reticulocyte(%)</td><td align="center" valign="middle" >9.6 &#177; 3.2</td><td align="center" valign="middle" >10.0 &#177; 3.5</td><td align="center" valign="middle" >9.1 &#177; 2.4</td><td align="center" valign="middle" >0.488</td></tr><tr><td align="center" valign="middle" >BUN (mmol/l)</td><td align="center" valign="middle" >2.8 &#177; 0.8</td><td align="center" valign="middle" >2.8 &#177; 0.9</td><td align="center" valign="middle" >2.9 &#177; 1.0</td><td align="center" valign="middle" >0.891</td></tr><tr><td align="center" valign="middle" >Uricacid (&#181;mol/l)</td><td align="center" valign="middle" >374.9 &#177; 113</td><td align="center" valign="middle" >374.9 &#177; 125.0</td><td align="center" valign="middle" >381.0 &#177; 101.2</td><td align="center" valign="middle" >0.898</td></tr><tr><td align="center" valign="middle" >Creatinine (&#181;mol/l)</td><td align="center" valign="middle" >56.6 &#177; 13.3</td><td align="center" valign="middle" >60.2 &#177; 14.2</td><td align="center" valign="middle" >54.0 &#177; 11.5</td><td align="center" valign="middle" >0.508</td></tr><tr><td align="center" valign="middle" >eGFR, ml/min/1.73 m<sup>2</sup></td><td align="center" valign="middle" >164.7 &#177; 36.4</td><td align="center" valign="middle" >164.3 &#177; 37.2</td><td align="center" valign="middle" >165.3 &#177; 35.8</td><td align="center" valign="middle" >0.890</td></tr><tr><td align="center" valign="middle" >ACR (mg/g)</td><td align="center" valign="middle" >38.3 &#177; 6.3</td><td align="center" valign="middle" >33.5 &#177; 7.7</td><td align="center" valign="middle" >44.1 &#177; 6.0</td><td align="center" valign="middle" >0.320</td></tr></tbody></table></table-wrap><p>Data are expressed as mean &#177; standard deviation, absolute frequency (n) and relative frequency (in percent) Abbreviations: BP, blood pressure HT, hypertension M, male F, female SBP, systolic blood presure DBP, diastolic blood pressure MAP, mean arterial blood pressure PP, pulse pressure BMI, body mass index WC, waist circumference HU, VOC, vaso-occlusive crisis hydroxyurea AON, aseptic osteonecrosis Hb, hemoglobin Ht, hematocrit BUN, blood urea nitrogen eGFR, estimated glomerular filtration rate.</p><p>creatinine and tricuspid regurgitant jet velocity (TRV) in SCD patients with relative hypertension in comparison to those with normal BP. They concluded that BP 120 - 139/70 - 89 mmHg defines a category of relative systemic hypertension in SCD patients that is associated with an increased risk of pulmonary artery hypertension and renal dysfunction.</p><p>Systemic hypertension was not a common finding in the present case series. Our finding agrees with previous reports of a paradoxical low prevalence of systemic hypertension in SCD in spite of endothelial dysfunction, chronic</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Cardiovascular risk factors in the study population as a whole and according to BP pattern status</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variables</th><th align="center" valign="middle" >All n = 103</th><th align="center" valign="middle" >Normal BP n = 56</th><th align="center" valign="middle" >Relative HT n = 47</th><th align="center" valign="middle" >p</th></tr></thead><tr><td align="center" valign="middle" >Age, years (n,%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.950</td></tr><tr><td align="center" valign="middle" >18 - 28</td><td align="center" valign="middle" >71(68.9)</td><td align="center" valign="middle" >38(67.9)</td><td align="center" valign="middle" >33(70.2)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >29 - 39</td><td align="center" valign="middle" >23(22.3)</td><td align="center" valign="middle" >13(23.2)</td><td align="center" valign="middle" >10(23.3)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >40 - 50</td><td align="center" valign="middle" >9(8.7)</td><td align="center" valign="middle" >5(8.9)</td><td align="center" valign="middle" >4(8.5)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Alcohol (n, %)</td><td align="center" valign="middle" >6(5.8)</td><td align="center" valign="middle" >3(5.4)</td><td align="center" valign="middle" >3(6.4)</td><td align="center" valign="middle" >0.574</td></tr><tr><td align="center" valign="middle" >Smoking (n, %)</td><td align="center" valign="middle" >5(4.9)</td><td align="center" valign="middle" >0(0.0)</td><td align="center" valign="middle" >5(10.6)</td><td align="center" valign="middle" >0.018</td></tr><tr><td align="center" valign="middle" >Increased PP (n, %)</td><td align="center" valign="middle" >6(5.8)</td><td align="center" valign="middle" >0(0.0)</td><td align="center" valign="middle" >6(12.8)</td><td align="center" valign="middle" >0.008</td></tr><tr><td align="center" valign="middle" >BMI &lt; 18.5 Kg/m<sup>2</sup>, n(%)</td><td align="center" valign="middle" >47(45.6)</td><td align="center" valign="middle" >29(51.8)</td><td align="center" valign="middle" >18(38.3)</td><td align="center" valign="middle" >0.012</td></tr><tr><td align="center" valign="middle" >Central obesity, n(%)</td><td align="center" valign="middle" >8(7.8)</td><td align="center" valign="middle" >2(3.6)</td><td align="center" valign="middle" >6(12.8)</td><td align="center" valign="middle" >0.005</td></tr><tr><td align="center" valign="middle" >Hb &lt; 80 g/l (n, %)</td><td align="center" valign="middle" >44(42.7)</td><td align="center" valign="middle" >22(39.3)</td><td align="center" valign="middle" >22(46.8)</td><td align="center" valign="middle" >0.028</td></tr><tr><td align="center" valign="middle" >Hyperuricemia (n, %)</td><td align="center" valign="middle" >43(41.7)</td><td align="center" valign="middle" >16(28.6)</td><td align="center" valign="middle" >27(57.4)</td><td align="center" valign="middle" >0.036</td></tr><tr><td align="center" valign="middle" >RKF, n(%)</td><td align="center" valign="middle" >4(3.9)</td><td align="center" valign="middle" >2(3.6)</td><td align="center" valign="middle" >2(6.4)</td><td align="center" valign="middle" >0.622</td></tr><tr><td align="center" valign="middle" >Microalbuminuria (n,%)</td><td align="center" valign="middle" >31(30.1)</td><td align="center" valign="middle" >10(17.9)</td><td align="center" valign="middle" >21(44.7)</td><td align="center" valign="middle" >0.038</td></tr></tbody></table></table-wrap><p>Data are expressed as absolute frequency (n) and relative frequency (in percent) Abbreviations: HT, hypertension, BP blood pressure,PP pulse pressure BMI, body mass index Hb, hemoglobin RKF : eGFR &lt; 60 ml/min/1.73 m<sup>2</sup>.</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Univariate and multivariate factors associated with relative hypertension in the study population in logistic regression analysis</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Variable</th><th align="center" valign="middle"  colspan="4"  >Univariate Multivariate</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >p</td><td align="center" valign="middle" >OR (95% IC)</td><td align="center" valign="middle" >p</td><td align="center" valign="middle" >ORa (95% IC)</td></tr><tr><td align="center" valign="middle" >Leg ulcer (yes vs no)</td><td align="center" valign="middle" >0.015</td><td align="center" valign="middle" >1.92(1.77 - 4.72)</td><td align="center" valign="middle" >0.016</td><td align="center" valign="middle" >2.05 (1.77 - 5.18)</td></tr><tr><td align="center" valign="middle" >Central obesity (yes vs no)</td><td align="center" valign="middle" >0.006</td><td align="center" valign="middle" >3.92(1.28 - 5.12)</td><td align="center" valign="middle" >0.001</td><td align="center" valign="middle" >3.32 (1.28 - 6.24)</td></tr><tr><td align="center" valign="middle" >Smoking (yes vs no)</td><td align="center" valign="middle" >0.015</td><td align="center" valign="middle" >5.12(1.55 - 7.45)</td><td align="center" valign="middle" >0.017</td><td align="center" valign="middle" >5.02 (1.51 - 9.50)</td></tr><tr><td align="center" valign="middle" >Hyperuricemia (yes vs no)</td><td align="center" valign="middle" >0.008</td><td align="center" valign="middle" >3.25(1.57-4.74)</td><td align="center" valign="middle" >0.796</td><td align="center" valign="middle" >1.12 (0.47 - 2.67)</td></tr><tr><td align="center" valign="middle" >Microalbuminuria (yes vs no)</td><td align="center" valign="middle" >0.013</td><td align="center" valign="middle" >2.17(1.50 - 2.73)</td><td align="center" valign="middle" >0.035</td><td align="center" valign="middle" >3.44 (1.44 - 5.76)</td></tr><tr><td align="center" valign="middle" >Hb &lt; 80 g/l (yes vs no)</td><td align="center" valign="middle" >0.003</td><td align="center" valign="middle" >3.36(1.62 - 4.98)</td><td align="center" valign="middle" >0.224</td><td align="center" valign="middle" >1.67 (0.73 - 3.90)</td></tr><tr><td align="center" valign="middle" >Constant</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.09</td><td align="center" valign="middle" >0.281</td></tr></tbody></table></table-wrap><p>Variables not entered in the model:PP (pulse pressure).</p><p>inflammation and vasculopathy, well-known risk factors for the development and progression of hypertension in the general population [<xref ref-type="bibr" rid="scirp.83414-ref1">1</xref>] . The incidence of hypertension among patients with SCD has been reported to be markedly lower than that of the general population and some patients may have lower than normal BP levels [<xref ref-type="bibr" rid="scirp.83414-ref22">22</xref>] . Potential mechanisms underlying this low prevalence of hypertension in SCD include premature deaths that remove those individuals whose BP might reach hypertensive levels in middle adulthood, higher urinary sodium loss due to hyposthenuria, systemic vasodilatation compensating for microcirculatory flow disturbances, increased production of prostaglandins, and subsequent reduced vascular reactivity [<xref ref-type="bibr" rid="scirp.83414-ref21">21</xref>] [<xref ref-type="bibr" rid="scirp.83414-ref22">22</xref>] . This observation have important clinical implications that include the possibility that relatively normal BP levels actually represent significant hypertension with the attendant risks of adverse cardiovascular and renal outcomes [<xref ref-type="bibr" rid="scirp.83414-ref22">22</xref>] . In line with the latter observation, some reports have indicated that the prevalence of systemic hypertension in SCD rely upon BP parameters considered to define hypertension and the setting of BP measurement. In this regard, Novelli et al. [<xref ref-type="bibr" rid="scirp.83414-ref1">1</xref>] found that pulse pressure, unlike other BP parameters, is associated with markers of hemolytic anemia and cardiovascular risk. Indeed, pulse pressure, SBP, DBP, and MAP were associated with reticulocyte count and hemolytic index. In the present study, patients with relative hypertension in spite of their younger age had in average increased PP levels compared to normotensive ones. Although elevated PP is a marker of arterial stiffness in old people, the association of PP and relative hypertension might be related to increased stroke volume as a compensatory mechanism, similar to that seen in patients with clinical hemolytic anemia [<xref ref-type="bibr" rid="scirp.83414-ref1">1</xref>] . Using ambulatory blood pressure monitoring (ABPM) in SCD patients, Becker et al. [<xref ref-type="bibr" rid="scirp.83414-ref5">5</xref>] reported a 35% and 56% prevalence of unrecognized hypertension and non-dipping blood pressure pattern, respectively. They concluded that BP abnormalities in SCD are more common than usually reported. Apart from blood viscosity abnormalities, renal dysfunction could also contribute to the relative increase in blood pressure in SCD patients [<xref ref-type="bibr" rid="scirp.83414-ref23">23</xref>] [<xref ref-type="bibr" rid="scirp.83414-ref24">24</xref>] [<xref ref-type="bibr" rid="scirp.83414-ref25">25</xref>] .</p><p>Leg ulcer, central obesity, smoking and microalbuminuria were the main factors significantly associated with relative hypertension in the present study. The association of leg ulcer with relative hypertension could be explained by increased viscosity [<xref ref-type="bibr" rid="scirp.83414-ref2">2</xref>] [<xref ref-type="bibr" rid="scirp.83414-ref26">26</xref>] translated in the present study by higher levels of hematocrit in SCD patients with relative hypertension compared to those with normal BP. Indeed, it has been reported that the development of complications in SCD rely upon two phenotypes characterized by either a state of hyperhemolysis or hyperviscosity [<xref ref-type="bibr" rid="scirp.83414-ref15">15</xref>] [<xref ref-type="bibr" rid="scirp.83414-ref27">27</xref>] [<xref ref-type="bibr" rid="scirp.83414-ref28">28</xref>] . The hyperviscosity phenotype with subsequent ischemia confers a high risk of complications such as VOC and aseptic osteonecrosis whereas the hyperhemolysis phenotype with subsequent endothelial dysfunction and chronic inflammation exposes SCD patients to complications such as leg ulcer, priapism, and pulmonary artery hypertension [<xref ref-type="bibr" rid="scirp.83414-ref22">22</xref>] [<xref ref-type="bibr" rid="scirp.83414-ref28">28</xref>] . Central obesity as well as smoking may induce relative increase in BP in SCD patients through direct effect on the kidneys and/or insulin resistance-induced activation of the sympathetic nervous system and renin angiotensin aldosterone system [<xref ref-type="bibr" rid="scirp.83414-ref14">14</xref>] [<xref ref-type="bibr" rid="scirp.83414-ref29">29</xref>] [<xref ref-type="bibr" rid="scirp.83414-ref30">30</xref>] . Microalbuminuria in SCD could be both a cause and a consequence of high blood pressure. Sung et al. [<xref ref-type="bibr" rid="scirp.83414-ref31">31</xref>] reported in a prospective longitudinal studies that even with the normal range of urinary albumin excretion (UAE), an increase in urinary albumin to creatinine ratio (UACR) is associated with an increased risk for incident hypertension and cardiovascular mortality. Albuminuria could also be a phenotype of systemic arterial endothelial damage caused by high BP or dysfunction of the endothelium of the glomerular capillary resulting in altered glomerular filtration function [<xref ref-type="bibr" rid="scirp.83414-ref32">32</xref>] . Indeed, Albuminuria is not only a predictor of development and progression of diabetic and nondiabetic renal diseases, but is a marker of endothelial dysfunction [<xref ref-type="bibr" rid="scirp.83414-ref33">33</xref>] .</p><p>The interpretation of the results of the present study should take into account of some limitations. First, its cross-sectional design precludes the establishment of temporal associations between variables of interest. Second, the small did not confer much power to statistical tests to identify additional association between variables of interest. Third, clinical and biological parameters were assessed only once with potential risks of under or overestimation of their true values.</p></sec><sec id="s5"><title>5. Conclusion</title><p>Relative hypertension was a common finding in the present case series and associated with traditional cardiovascular risk factor as well as factors specific to SCD highlighting the need for measures to prevent its progression towards systemic hypertension and associated cardiovascular and renal disease.</p></sec><sec id="s6"><title>Acknowledgements</title><p>We would like to sincerely thank all the staff of hospitals involved in the present study with special thanks to Professor Dr. Leon Tshilolo, Dr. J&#233;remie Muwonga and Dr. Placide Manzombi. We remain indebted to Dr. Ernest NGONG and Dr. Christelle Ndjali for their commitment as well as to all the participants for their invaluable contribution to the knowledge of sickle cell disease and associated complications.</p></sec><sec id="s7"><title>Author’s Contribution</title><p>MPI drafted the protocol, collected data, participated in data processing and analysis, drafted the manuscript; LFB revised the protocol and the manuscript, participated in data analysis; MJR revised the protocol and the manuscript, participated in data analysis; NA proceeded to data analysis and revised the manuscript; BJB revised the manuscript; MVM revised the manuscript; LAL revised the manuscript; ZCV revised the manuscript; KFP revised manuscript; NYM revised the manuscript; EYM revised the manuscript; MMM revised the manuscript and participated in data analysis; KEM revised the manuscript; ICK revised the manuscript; EPM revised the manuscript; NMN revised the manuscript.</p></sec><sec id="s8"><title>Cite this paper</title><p>Mboliasa, P.I., Lepira, F.B., Makulo, J.R., Nkodila, A., Sumaili, E.K., Bukabau, J.B., Mokoli, V.M., Longo, A.L., Zinga, C.V., Kanjingulu, F.M.P., Nlandu, Y.M., Engole, Y.M., Mukendi, M.M., Kadima, E.M., Ilunga, C.K., Ekulu, P.M. and Nseka, N.M.N. (2018) Blood Pressure Patterns and Factors Associated with Relative Hypertension among Steady State Sickle Cell Disease Patients in Kinshasa, Democratic Republic of the Congo: A Cross-Sectional Study. World Journal of Cardiovascular Diseases, 8, 217-228. https://doi.org/10.4236/wjcd.2018.83021</p></sec></body><back><ref-list><title>References</title><ref id="scirp.83414-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Novelli, E.M., Hildeshein, M., Rosano, C., et al. (2014) Elevated Pulse Pressure Is Associated with Hemolysis, Proteinuria, and Chronic Kidney Disease. In Sickle Cell Disease. Plos One, 9, e114309. https://doi.org/10.1371/journal.pone.0114309</mixed-citation></ref><ref id="scirp.83414-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Lamarre, Y., Lalanne-Mistrih, M.-L., Romana, M., et al. (2013) Male Gender, Increased Blood Viscosity, Body Mass Index and Triglyceride Levels Are Independently Associated with Systemic Relative Hypertension in Sickle Cell Anemia. PLoS One, 8, e66004. https://doi.org/10.1371/journal.pone.0066004</mixed-citation></ref><ref id="scirp.83414-ref3"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Berekat-Haddad</surname><given-names> C. </given-names></name>,<etal>et al</etal>. (<year>2014</year>)<article-title>Prevalence of High Blood Pressure, Heart Disease, Thalassemia Sickle Cell Disease, and Iron Deficiency Anemia among the UAE Adolescent Population</article-title><source> Injury Prevention</source><volume> 20</volume>,<fpage> 121</fpage>-<lpage>127</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.83414-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Bordas, P., Huang, A., O’Riopdan, M.A., et al. (2013) Prevalence of Hypertension and Abnormal Kidney Function in Children with Sickle Cell Disease. A Cross-Sectional Review. BMC Nephrology, 14, 237.  
https://doi.org/10.1186/1471-2369-14-237</mixed-citation></ref><ref id="scirp.83414-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Becker, A.M., Goldberg, J.H., Henson, M., et al. (2014) Blood Pressure Abnormalities in Children with Sickle Cell Disease. Pediatric Blood &amp; Cancer, 61, 518-522.  
https://doi.org/10.1002/pbc.24843</mixed-citation></ref><ref id="scirp.83414-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Gordeuck, V.R., Sachdev, V., Taylor, J.G., et al. (2008) Relative Systemic Hypertension in Patients with Sickle Cell Disease Is Associated with Risk of Pulmonary Hypertension and Renal Insufficiency. American Journal of Hematology, 83, 15-18.  
https://doi.org/10.1002/ajh.21016</mixed-citation></ref><ref id="scirp.83414-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Tshilolo, L., Summa, V., Gregorj, C., et al. (2012) Foetal Haemoglobin and Hematological Features in Congolese Patients with Sickle Cell Anaemia. Anemia, 2012, 105349. https://doi.org/10.1155/2012/105349</mixed-citation></ref><ref id="scirp.83414-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Aloni, M.N., Ngiyulu, R.M., Gini-Ehungu, J.L., et al. (2014) Renal Function in Children Suffering Sickle Cell Disease: Challenge of Early Detection in Highly Resource-Scarce Setting. PLoS One, 9, e96561.  
https://doi.org/10.1371/journal.pone.0096561</mixed-citation></ref><ref id="scirp.83414-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Itokua, K.E., Makulo, J.R., Lepira, F.B., et al. (2016) Albuminuria, Serum Antioxidant Enzyme Levels and Markers of Hemolysis and Inflammation in Steady State Children with Sickle Cell Anemia. A Clinical-Based Cross-Sectional Study. BMC Nephrology, 17, 178. https://doi.org/10.1186/s12882-016-0398-0</mixed-citation></ref><ref id="scirp.83414-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Berchel, C., Diara, J.P. and Loret, H. (1992) Natural History of Sickle Cell Disease. Rev Prat, 42, 1885-1891.</mixed-citation></ref><ref id="scirp.83414-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Orth, S.R., Stockman, A., Conradt, C., et al. (1998) Smoking as a Risk Factor for End-Stage Renal Failure in Men with Primary Renal Disease. Kidney International, 54, 926-931. https://doi.org/10.1046/j.1523-1755.1998.00067.x</mixed-citation></ref><ref id="scirp.83414-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2002) The World Health Report 2002. Reducing Risks, Promoting Healthy Life. World Health Organization, Geneva.</mixed-citation></ref><ref id="scirp.83414-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">World Health Organization (2000) The Problem of Overweight and Obesity: Managing: Preventing and Managing the Global Epidemic. Report Series 894, WHO, Geneva, 537.</mixed-citation></ref><ref id="scirp.83414-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Alberti, K.G., Zimmet, P. and Shaw, J. (2005) The Metabolic Syndrome a New Worldwide Definition. The Lancet, 366, 1059-1062.  
https://doi.org/10.1016/S0140-6736(05)67402-8</mixed-citation></ref><ref id="scirp.83414-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Kato, G.J., Steinberg, M.H. and Gladwin, M.T. (2009) Vasculopathy in Sickle Cell Disease: Biology, Pathophysiology, Genetics, Translational Medicine and New Research Directions. American Journal of Hematology, 84, 618-625.  
https://doi.org/10.1002/ajh.21475</mixed-citation></ref><ref id="scirp.83414-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Romi, M.M., Arfian, N., Tranggono, U., et al. (2017) Uric Acid Causes Kidney Injury through Inducing Fibroblast Expansion, Endothelin-1 Expression and Inflammation. BMC Nephrology, 18, 326. https://doi.org/10.1186/s12882-017-0736-x</mixed-citation></ref><ref id="scirp.83414-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Arlet, J.B., Ribeil, J.R., Chatellier, G., et al. (2012) Determination of the Best Method to Estimate Glomerular Filtration Rate from Serum Creatinine in Adult Patients with Sickle Cell Disease: A Prospective Observational Cohort Study. BMC Nephrology, 13, 83. https://doi.org/10.1186/1471-2369-13-83</mixed-citation></ref><ref id="scirp.83414-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Kidney Disease Improving Global Outcomes (2013) Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International, 3, 5-1418.</mixed-citation></ref><ref id="scirp.83414-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Vasquez, B., Shah, B., Zhang, X., et al. (2014) Hyperfiltration Is Associated with the Development of Microalbuminuria in Patients with Sickle Cell Anemia. American Journal of Hematology, 89, 1156-1157. https://doi.org/10.1002/ajh.23817</mixed-citation></ref><ref id="scirp.83414-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Benneh-Akwasi Kuma, A., Owuwu-Ansah, A.T., Ampomah, M.A., et al. (2018) Prevalence of Relative Systemic Hypertension in Adults with Sickle Cell Disease in Ghana. PLoS ONE, 13, e0190347. https://doi.org/10.1371/journal.pone.0190347</mixed-citation></ref><ref id="scirp.83414-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Makubi, A., Mmbando, B.P., Novelli, E.M., et al. (2017) Rates and Risk Factors of Hypertension in Adolescents and Adults with Sickle Cell Anemia in Tanzania: 10 Years’ Experience. British Journal of Haematology, 177, 930-937.  
https://doi.org/10.1111/bjh.14330</mixed-citation></ref><ref id="scirp.83414-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Alhwiesh, A. (2014) An Update on Sickle Cell Nephropathy. Saudi Journal of Kidney Diseases and Transplantation, 25, 249-265.  
https://doi.org/10.4103/1319-2442.128495</mixed-citation></ref><ref id="scirp.83414-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Nath, K.A. and Hebbel, R.P. (2015) Renal Manifestations and Mechanisms. Nature Reviews Nephrology, 11, 161-171. https://doi.org/10.1038/nrneph.2015.8</mixed-citation></ref><ref id="scirp.83414-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Lionnet, F., Arlet, J.B., Bartolucci, P., et al. (2009) Guidelines for the Management of Adult Sickle Cell Disease. La Revue de Médecine Interne, 30, S162-S223.  
https://doi.org/10.1016/j.revmed.2009.07.001</mixed-citation></ref><ref id="scirp.83414-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Lionnet, F. and Steichen, O. (2010) Relative Hypertension of Sickle Cell Disease Patients. Revue du Praticien, 60, 658.</mixed-citation></ref><ref id="scirp.83414-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Oguanobi, N.I., Onwubere, B.J.C., Ibegbulam, O.G., et al. (2010) Arterial Blood Pressure in Adult Nigerians with Sickle Cell Anemia. Journal of Cardiology, 56, 326-331. https://doi.org/10.1016/j.jjcc.2010.07.001</mixed-citation></ref><ref id="scirp.83414-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Dubert, A., Menet, A., Tolo, A. and Diallo, D. (2015) Association between Chronic Hyperhemolysis and Vascular Complications of Sickle Cell Disease in Sub-Saharan Africa. Revue de Médecine Interne, 36, A95.  
https://doi.org/10.1016/j.revmed.2015.10.332</mixed-citation></ref><ref id="scirp.83414-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Ballas, S.K., Kesen, M.R. and Lutty, G.A. (2012) Beyond the Definitions of the Phenotypic Complications of Sickle Cell Disease: An Update on Management. Scientific World Journal, 2012, Article ID: 949535. https://doi.org/10.1100/2012/949535</mixed-citation></ref><ref id="scirp.83414-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Akingbola, T.S., Tayo, B.O., Salako, B. and Lewis, L.J.E. (2014) Comparison of Patients from Nigeria and the USA Highlights Modifiable Risk Factors for Sickle Cell Anemia Complications. Hemoglobin, 38, 236-243.  
https://doi.org/10.3109/03630269.2014.927363</mixed-citation></ref><ref id="scirp.83414-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Korneeva, N.V. and Sirotin, B.Z. (2017) Microcirculatory Bed, Microcirculation, and Smoking-Associated Endothelial Dysfunction in Young Adults. Bulletin of Experimental Biology and Medicine, 162, 824-828.  
https://doi.org/10.1007/s10517-017-3722-1</mixed-citation></ref><ref id="scirp.83414-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Sung, K.C., Ryu, S., Lee, J.Y., et al. (2016) Urine Albumin/Creatinine Ratio below 30 mg/g Is a Predictor of Incident Hypertension and Cardiovascular Mortality. Journal of the American Heart Association, 5, e003245.  
https://doi.org/10.1161/JAHA.116.003245</mixed-citation></ref><ref id="scirp.83414-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Malik, A.R., Sultan, S., Turner, S.T., et al. (2007) Urinary Albumin Excretion Is Associated with Impaired Flow- and Nitroglycerine-Mediated Brachial Artery Vasodilatation in Hypertensive Adults. Journal of Human Hypertension, 21, 231-238.  
https://doi.org/10.1038/sj.jhh.1002143</mixed-citation></ref><ref id="scirp.83414-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Weir, M.R. (2007) Microalbuminuria and Cardiovascular Disease. Clinical Journal of the American Society of Nephrology, 2, 581-590.  
https://doi.org/10.2215/CJN.03190906</mixed-citation></ref></ref-list></back></article>